Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Journal of Colorado.
Press releases published on May 12, 2025
CXAUTO2025 Returns for 21st Annual Automotive Summit in Long Beach, CA
EIN Presswire
·
May 12, 2025
CXAUTO2025 will bring together leaders from OEMs, dealerships, finance, and technology to tackle the latest innovations in automotive customer experience. BOULDER, CO, UNITED STATES, May 12, 2025 /EINPresswire.com/ -- Thought Leadership Summits (TLS) is …
JPLoft Sets New Benchmark in eWallet App Development with AI-powered Solution
EIN Presswire
·
May 12, 2025
JPLoft sets a new standard in eWallet app development with an AI-powered solution, enhancing user experience, security, and transaction efficiency. DENVER, CO, UNITED STATES, May 12, 2025 /EINPresswire.com/ -- In a world where digital payments are …
Defend Client Confidentiality with Expert Cybersecurity Built for Colorado Law Firms
EIN Presswire
·
May 12, 2025
By protecting client information and maintaining compliance with industry regulations, we aim to be a trusted ally for Colorado attorneys. BOULDER, CO, UNITED STATES, May 12, 2025 /EINPresswire.com/ -- Cyber Tech Connection, a leading provider of …
ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ
GlobeNewswire
·
May 12, 2025
PRINCETON, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright …
Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering
GlobeNewswire
·
May 12, 2025
Hopewell, New Jersey, May 12, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally …
Constellation Software Inc. Announces Results for the First Quarter Ended March 31, 2025 and Declares Quarterly Dividend
GlobeNewswire
·
May 12, 2025
TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) (“Constellation” or the “Company”) today announced its financial results for the first quarter ended March 31, 2025 and declared a $1.00 per share dividend payable on July 11, …
Microvast Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 12, 2025
Record company Q1 revenue, increased 43.2% year over year to $116.5 million Gross margin increased from 21.2% to 36.9%, a 15.7 percentage point improvement year over year STAFFORD, Texas, May 12, 2025 (GLOBE NEWSWIRE) -- Microvast Holdings, Inc. (NASDAQ: …
3D Systems Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 12, 2025
ROCK HILL, S.C., May 12, 2025 (GLOBE NEWSWIRE) -- 3D Systems Corporation (NYSE:DDD) announced today its financial results for the first quarter ended March 31, 2025. Revenue of $95 million as growth in new hardware systems and related services was offset …
AirJoule Technologies Announces First Quarter 2025 Results
GlobeNewswire
·
May 12, 2025
RONAN, Mont., May 12, 2025 (GLOBE NEWSWIRE) -- AirJoule Technologies Corporation (NASDAQ: AIRJ) (“AirJoule Technologies” or the “Company”), the developer of the transformational AirJoule® system for separating pure water from air, today announced its first …
New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism
GlobeNewswire
·
May 12, 2025
COPENHAGEN, Denmark, May 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) continued to provide …
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
May 12, 2025
PHILADELPHIA, May 12, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context …
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 12, 2025
Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD‑1/L1 therapy SEED’s first‑in‑class RBM39 degrader, reported at AACR 2025 for its total tumor regression data in …
Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights
GlobeNewswire
·
May 12, 2025
FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Announced positive topline results from Phase 1 study of TNX- …
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
GlobeNewswire
·
May 12, 2025
MORRISTOWN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and …
Satellogic Secures Multi-Million Dollar Agreement with Asia Pacific Customer
GlobeNewswire
·
May 12, 2025
DAVIDSON, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Satellogic Inc. (NASDAQ: SATL), a leader in high-resolution Earth observation data, announced today it has entered into a multi-million dollar agreement with an Asia Pacific customer. The agreement provides …
Cellectis Reports Financial Results for the First Quarter 2025
GlobeNewswire
·
May 12, 2025
Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025 Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025 …
Editas Medicine Announces First Quarter 2025 Results and Business Updates
GlobeNewswire
·
May 12, 2025
Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) at ASGCT this week Company will also share in vivo …
Life360 Reports Record Q1 2025 Results
GlobeNewswire
·
May 12, 2025
Monthly Active Users Reached Approximately 83.7 million Record Q1 Global Net Additions to Paying Circles of 137 thousand - Reaching 2.4 million Total Total Quarterly Revenue Grew 32% Year-Over-Year to $103.6 million Annualized Monthly Revenue increased 38% …
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones
GlobeNewswire
·
May 12, 2025
FDA Breakthrough Device Designation Awarded to AVIM Therapy FDA IDE Approved for Virtue SAB U.S. Pivotal Trial for Launch NEW HOPE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a …
ODDITY Announces Block Trade of Class A Ordinary Shares
GlobeNewswire
·
May 12, 2025
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (the “Company”) (NASDAQ: ODD) today announced the sale of 5,500,000 shares of its Class A ordinary shares by an entity affiliated with Oran Holtzman, ODDITY co-founder and CEO. The transaction …